Lorem ipsum dolor sit amet, consectetur adipiscing elit

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

The unmet clinical need

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit
amet, consectetur ad
ipisicing elit, sed do
eiusmod tempor incididunt
ut labore et
dolore magna aliqua. Ut enim ad min
im veniam, quis nostrud exercitation ullamco laboris.

Latest press releases

Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion

Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion…

Latest press releases

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals AB (publ) today announces that the company has entered into an agreement with Pareto Securities AB to act as liquidity provider for Annexin's shares, listed on Nasdaq First…

Latest press releases

Interview and webinar published on Annexin’s ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof of Concept phase 2a…

Latest press releases

First patients treated in Annexin’s Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy…